Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes | Zendy

Marat Fudim | Zendy; Jennifer A. White | Zendy; Neha J. Pagidipati | Zendy; Yuliya Lokhnygina | Zendy; Julio Wainstein | Zendy; Ján Murín | Zendy; Nayyar Iqbal | Zendy; Peter Öhman | Zendy; Renato D. Lópes | Zendy; Barry Reicher | Zendy; Rury R. Holman | Zendy; Adrian F. Hernandez | Zendy; Robert J. Mentz | Zendy

Open Access

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes

Author(s) -

Marat Fudim,

Jennifer A. White,

Neha J. Pagidipati,

Yuliya Lokhnygina,

Julio Wainstein,

Ján Murín,

Nayyar Iqbal,

Peter Öhman,

Renato D. Lópes,

Barry Reicher,

Rury R. Holman,

Adrian F. Hernandez,

Robert J. Mentz

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.119.041659

Subject(s) - medicine , heart failure , ejection fraction , hazard ratio , exenatide , cardiology , diabetes mellitus , heart failure with preserved ejection fraction , population , type 2 diabetes , confidence interval , endocrinology , environmental health

Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baseline heart failure (HF) status. EQW's effects on secondary end points based on HHF status have not been reported. The objective was to explore the effects of EQW on secondary end points in patients with and without baseline HF and test the effects of EQW on recurrent HHF events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research